This company is no longer active
The company may no longer be operating, as it may be out of business. Find out why through their latest events.
Resumen de acción GMTX
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD).
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Competidores de Gemini Therapeutics, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.35 |
| 52 Week High | US$3.10 |
| 52 Week Low | US$1.16 |
| Beta | -0.12 |
| 1 Month Change | -21.51% |
| 3 Month Change | -17.68% |
| 1 Year Change | -53.61% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -86.89% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| GMTX | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | -12.9% | 2.6% | 1.6% |
| 1Y | -53.6% | 7.0% | 26.1% |
Rentabilidad vs. Industria: GMTX underperformed the US Biotechs industry which returned -10.7% over the past year.
Rentabilidad vs. Mercado: GMTX underperformed the US Market which returned -23.1% over the past year.
Volatilidad de los precios
| GMTX volatility | |
|---|---|
| GMTX Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 2.8% |
Precio estable de las acciones: GMTX's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: GMTX's weekly volatility (8%) has been stable over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2015 | 24 | Georges Gemayel | www.geminitherapeutics.com |
Resumen de fundamentos de Gemini Therapeutics, Inc.
| Estadísticas fundamentales de GMTX | |
|---|---|
| Capitalización bursátil | US$58.49m |
| Beneficios(TTM) | -US$43.42m |
| Ingresos (TTM) | n/a |
0.0x
Ratio precio-ventas (PS)-1.3x
Ratio precio-beneficio (PE)¿Está GMTX sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de GMTX | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$0 |
| Otros gastos | US$43.42m |
| Beneficios | -US$43.42m |
Últimos beneficios comunicados
Sep 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.00 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado GMTX a largo plazo?
Ver rendimiento histórico y comparativa